WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) announced the acceptance of five abstracts, including a late-breaking study, for presentation at the European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam. The research highlights the company’s advances in treating chronic hepatitis B (CHB) and the progress of innovative small-molecule therapeutics.
Key findings from the studies include the identification of baseline factors, such as HBsAg levels, that may predict functional cure outcomes in patients treated with imdusiran and pegylated interferon alfa-2a. One study noted significant HBV RNA reductions among patients achieving seroclearance, suggesting a strong link between RNA dynamics and treatment success.
Arbutus will also present early clinical data on AB-101, a small-molecule PD-L1 inhibitor. Preliminary findings indicate the drug is well-tolerated across multiple doses, showing rapid tissue distribution and promising pharmacodynamic effects in healthy participants. Studies on AB-101 in CHB patients are ongoing.
Additionally, a late-breaking abstract explores the safety and antiviral effects of combined imdusiran and VTP-300 treatments in non-cirrhotic CHB patients. Results highlight their potential in off-treatment viral suppression approaches.
The abstracts will be featured on May 7-8, 2025, during the Viral Hepatitis B and D sessions, providing a forum for Arbutus to share its scientific progress with global experts.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.